Mariot, Virginie
Joubert, Romain http://orcid.org/0000-0003-4902-2035
Hourdé, Christophe
Féasson, Léonard
Hanna, Michael
Muntoni, Francesco
Maisonobe, Thierry
Servais, Laurent
Bogni, Caroline
Le Panse, Rozen
Benvensite, Olivier
Stojkovic, Tanya
Machado, Pedro M. http://orcid.org/0000-0002-8411-7972
Voit, Thomas
Buj-Bello, Ana
Dumonceaux, Julie
Article History
Received: 7 February 2017
Accepted: 21 September 2017
First Online: 30 November 2017
Competing interests
: L.S. received consultancy fees from Roche, Avexis, Biogen, Biomarin, Sarepta, BMS, Pfizer, Dynacure, and Bamboo. He serves in the Steering committee of PTC therapeutics. M.H. has previously been a consultant for Novartis. P.M.M. received consultancy/speaker’s fees from AbbVie, Centocor, Janssen, Merck, Novartis and Pfizer. F.M. reports personal fees from Akashi Therapeutics, Biogen, BioMarin, Catabasis, Italfarmaco, Pfizer, Roche, Sarepta Therapeutics, and Trivorsan. A.B.-B. is an inventor of two issued patents on MTM1 gene therapy for myotubular myopathy and a scientific advisor for Audentes Therapeutics. A patent named “Myostatin companion diagnostic and biomarker” has been filed by University College London and includes T.V., V.M., and J.D. as named inventors. The remaining authors declare no competing financial interests.